This activity is jointly provided by Duke University Health System Department of Clinical Education and Professional Development and Haymarket Medical Education.
Supported by educational grants from Boehringer Ingelheim and Daiichi Sankyo, Inc.
Atrial fibrillation (AF) is associated with a 4- to 5-fold increase in the risk for ischemic stroke and systemic embolism, yet less than one-half of patients with AF undergo appropriate risk stratification and anticoagulant therapy. A challenge in the management of older patients with AF is balancing the need for anticoagulation to prevent stroke with the high risk of hemorrhage. This involves considering the limitations of traditional warfarin therapy and the complexities of newer anticoagulant treatments. This expert panel discussion features case examples highlighting effective clinician-patient communication about stroke prevention in AF.
Intended for primary care physicians, cardiologists, physician assistants, nurse practitioners, and hospitalists who treat patients with AF
After taking part in this educational activity, participants should be better able to:
Recognize the large degree of underutilization of anticoagulation in patients with AF and the resultant morbidity, mortality, and health care costs
Outline strategies recommended in clinical guidelines to assess risk for stroke and bleeding to optimize outcomes of anticoagulation therapy
Evaluate the limitations, risks, challenges, and opportunities surrounding traditional and current anticoagulation therapies
Implement strategies to improve communication and shared decision making between clinicians and patients/caregivers about the benefits and risks of anticoagulation therapy
Activity Medical Director James Daubert, MD Professor of Medicine Director, Clinical Electrophysiology Section Duke University Medical Center Durham, NC
Dr. Daubert is an expert reviewer for ACRA biopharma, Boston Scientific, Gilead Sciences, and VytronUS, Inc. He serves as an advisory board member for Biosense Webster Inc. and Gilead Sciences. Dr. Daubert is principal investigator for Biosense Webster Inc., Biotronik, Boston Scientific, Gilead Sciences, Medtronic, and St. Jude. He is a speaker for Biotronik, Boston Scientific, and Medtronic. Dr. Daubert is also a consultant for CardioFocus and Orexigen Therapeutics, Inc.
CHAIRPERSON Samuel Z. Goldhaber, MD Senior Physician, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School Boston, MA
Dr. Goldhaber is a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Eisai, EKOS Corporation, Pfizer, Portola Pharmaceuticals, and Sanofi. Dr. Goldhaber is also principal investigator for Bristol-Myers Squibb, Daiichi Sankyo, Inc., Eisai, and Orphan – EKOS.
FACULTY Christian T. Ruff, MD, MPH TIMI Study Group Cardiovascular Division Brigham and Women’s Hospital Harvard Medical School Boston, MA
Dr. Ruff is an advisory board member for Bayer Pharmaceuticals, Boehringer Ingelheim, Daiichi Sankyo, Inc., and Portola Pharmaceuticals.
Elaine Hylek, MD Professor of Medicine Resident Unit-Section of General Internal Medicine Boston University School of Medicine Boston, MA
Dr. Hylek is an advisory board member for Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Inc., Janssen, and Pfizer. Dr. Hylek serves on the executive steering committee for Bristol-Myers Squibb and Ortho-McNeil. She is also on the speakers bureau for Bayer Pharmaceuticals, Boehringer Ingelheim, and Bristol-Myers Squibb.
Publishing Staff Disclosures
The following Haymarket Medical Education planning committee member, Mary Jo Krey, hereby states that she or her spouse/life partner does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development and Haymarket Medical Education for the advancement of patient care. The Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the health care team.
Duke University Health System Department of Clinical Education and Professional Development designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
To obtain credit, a score of 80% or better is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can then access at any time.
If you have any questions relating to the accreditation of this activity, please contact Duke CME at 919-401-1200.